Xenon Pharmaceuticals Inc. (XENE)
| Previous close | 26.48 |
| Open | 26.47 |
| Bid | 25.12 x 800 |
| Ask | 31.95 x 1200 |
| Day's range | 24.92 - 26.72 |
| 52-week range | 14.27 - 36.42 |
| Volume | |
| Avg. volume | 513,690 |
| Market cap | 1.296B |
| Beta (5Y monthly) | 1.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.55 |
| Earnings date | 28 Feb 2022 - 04 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 45.33 |
- GlobeNewswire
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. The U.S. Food and Drug Administration (FDA) accepted Neurocrine’s protocol amendment that expands the study population to incl
- GlobeNewswire
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We are entering 2022 with an immense amount of positive momentum, building upon the strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial announced in the fourth quarter of 2021. We have set clear business objectives f
- Simply Wall St.
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
